Want to see SE:ACOU full AI Analyst Report?
ACOU Stock Chart & Stats
kr2.99
-kr0.07(-1.88%)
At close: 4:00 PM EDT
kr2.99
-kr0.07(-1.88%)
Day’s Range― - ―
52-Week Rangekr2.03 - kr5.16
Previous CloseN/A
Volume11.66K
Average Volume (3M)24.45K
Market Cap
kr63.07M
Enterprise Valuekr70.31
Total Cash (Recent Filing)kr9.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding21,163,902
10 Day Avg. Volume13,943
30 Day Avg. Volume24,450
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTTM revenue growth to 7.97m and 7.6% indicates customer demand is expanding, providing a larger base from which AcouSort can commercialize its acoustofluidic modules and integration work. If sustained, this growth could improve operating leverage and support broader adoption across laboratory and bioprocessing workflows.
Debt-free Balance SheetThe absence of reported debt materially reduces solvency and refinancing risk, preserving financial flexibility during the company’s development phase. A debt-free structure also avoids interest burdens and gives AcouSort more discretion over future investment, partnerships, or funding decisions as commercialization progresses.
Specialized Technology PlatformAcouSort’s specialized acoustofluidic platform addresses cell and particle separation without labels and can be delivered as modules or integrated systems. Its applicability to cell therapy manufacturing, diagnostics, and research creates several potential workflow applications and supports integration into customer instrumentation.
Bears Say
Deeply Negative ProfitabilityNegative gross profit and large EBIT and net losses show that AcouSort has not yet established a stable, scalable profit model. Even with some year-over-year loss narrowing, deeply negative margins can constrain reinvestment capacity and make financial performance dependent on continued funding.
Persistent Cash BurnSizable negative operating and free cash flow indicate that the business is consuming cash rather than funding itself through operations. The reversion from positive cash flow in 2022 to cash burn in 2023–TTM suggests elevated funding needs will remain until profitability and operating economics improve.
Shrinking Equity BaseThe sharp decline in equity reflects the cumulative impact of ongoing losses and reduces the company’s financial cushion. If losses continue, AcouSort may need additional funding, and the balance-sheet analysis specifically identifies potential future dilution risk as a consequence.
ACOU FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was kr2.03 and its highest was kr5.16 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is kr63.07M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Nov 25, 2026 which is in 65 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on Aug 26, 2026. The company reported -kr0.167 earnings per share for the quarter.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -kr0.167 in its last earnings report. Following the earnings report the stock price went up 7.942%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in SE:ACOU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.